Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Heldens JGM et al. – The protection against A/equine/Kentucky/95 (H3N8) was evidenced by a reduction of clinical signs of influenza, a reduction of virus excretion and a reduction of fever. The vaccine was shown to be safe in pregnant mares, foals and is used safely since 2 years as a commercial vaccine in Europe.

Related Articles

Update on 2009 pandemic influenza A (H1N1) virus
Cleveland Clinic Journal of Medicine, 10/05/09    Relevance Score: 71%

Pandemic 2009 Influenza Update: Pandemrix data on co-administration with annual seasonal influenza vaccine
GlaxoSmithKline, 11/10/09    Relevance Score: 70%

H1N1 Vaccine Deliveries Begin. Early Doses to Arrive This Week
American Family Physician, 10/07/09    Relevance Score: 70%

Novartis completes shipment of US supply of Fluvirin seasonal influenza vaccine
Novartis, 10/07/09    Relevance Score: 70%

One Dose of H1N1 Vaccine Immunogenic in High Percentage of Youth Ages 10 to 17. Younger Children Likely Will Need Two Doses
American Family Physician, 10/05/09    Relevance Score: 70%

Today in Vaccine/Immunotherapy...keeping you current

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
New England Journal of Medicine, 12/17/09

A Novel Influenza A (H1N1) Vaccine in Various Age Groups
New England Journal of Medicine, 12/17/09

Efficacy and Safety of Pentavalent Human-Bovine Reassortant Rotavirus Vaccine When Administered With Greater Than 10 Weeks Between Doses
The Pediatric Infectious Disease Journal, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address